Accelerating the Development of Novel Anti-VEGF, VEGF-independent Therapies & Drug Delivery Options To Reduce Clinical Burden, Widen Therapeutic Index & Treatment Options for Non-responders
The 2022 Summit will include interactive presentations and panel discussions, covering challenging questions for the whole research community such as:
- What are the future directions for anti-VEGF therapy to increase patient response rates, prolong treatment durability and reduce clinical burden?
- Where is the clinical success for targeting VEGF-independent pathways in this multifactorial disease?
- What interventions beyond anti-VEGF give treatment options for refractory or not optimally treated patients?
- How are drug developers using various drug delivery methods – topical, intravitreal, suprachoroidal, port delivery – to expand the therapeutic window?
- How has optical coherence tomography (OCT) imaging, including at-home diagnostic testing, and artificial intelligence-enabled programming personalized wet AMD and DME treatment and supported clinical trials?
As the only industry-led forum solely dedicated to finding long-lasting therapeutic interventions for wet AMD and DME, attendees will have the opportunity to review the multiple pathological mechanisms being actively targeted, identify the latest clinical data from anti-VEGF suppression (antibody fragments, delivery systems, bispecific antibodies, gene therapy), combinational approaches, non- VEGF pathways (integrin and TKI’s) and VEGF-independent (such as targeting plasma kallikrein) therapies.
Meet the leading ophthalmology drug developers from big pharma, biotech and academia searching for treatment breakthroughs and actively gathering clinical evidence to demonstrate a favourable benefit/risk ratio for future products to regulators, clinicians and payers.
Join us next April to hear their latest clinical development programs and identify future portfolio strategies for your organisation.
To know more visit: https://ter.li/m98rr7